

Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/C1D190043670EN.html>

Date: January 2022

Pages: 74

Price: US\$ 3,250.00 (Single User License)

ID: C1D190043670EN

Abstracts

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.

This report contains market size and forecasts of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global, including the following market information:

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market was valued at 7854.6 million in 2021 and is projected to reach US\$ 11030 million by 2028, at a CAGR of 5.0% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Oral Therapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation and Bayer AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, by Type, 2021 (%)

Oral Therapy

Injectable Therapy

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospitals & Clinics

Home Settings

Ambulatory Surgical Centers (ASCs)

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Astellas Inc.

Johnson & Johnson

Sanofi S.A

Dendreon Corporation

Bayer AG

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market
- 3.2 Top Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies Ranked by Revenue
- 3.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Companies in Global Market, by Revenue in 2021

3.5 Global Companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Product Type

3.6 Tier 1, Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Players in Global Market

3.6.1 List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Oral Therapy

4.1.3 Injectable Therapy

4.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Market Size, 2021 & 2028

5.1.2 Hospitals & Clinics

5.1.3 Home Settings

5.1.4 Ambulatory Surgical Centers (ASCs)

5.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Castration-Resistant Prostate Cancer

(CRPC)/HRPCA Therapeutics Revenue, 2017-2028

6.3.2 US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market

Size, 2017-2028

6.3.3 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Market Size, 2017-2028

6.3.4 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue, 2017-2028

6.4.2 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Market Size, 2017-2028

6.4.3 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Market Size, 2017-2028

6.4.4 U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market

Size, 2017-2028

6.4.5 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market

Size, 2017-2028

6.4.6 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

Market Size, 2017-2028

6.4.7 Nordic Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Market Size, 2017-2028

6.4.8 Benelux Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028

6.5.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.5.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.5.4 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.5.6 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028

6.6.2 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.6.3 Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028

6.7.2 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.7.3 Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

6.7.5 UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Astellas Inc.

7.1.1 Astellas Inc. Corporate Summary

- 7.1.2 Astellas Inc. Business Overview
- 7.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
- 7.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
- 7.1.5 Astellas Inc. Key News
- 7.2 Johnson & Johnson
 - 7.2.1 Johnson & Johnson Corporate Summary
 - 7.2.2 Johnson & Johnson Business Overview
 - 7.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
 - 7.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
 - 7.2.5 Johnson & Johnson Key News
- 7.3 Sanofi S.A.
 - 7.3.1 Sanofi S.A Corporate Summary
 - 7.3.2 Sanofi S.A Business Overview
 - 7.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
 - 7.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
 - 7.3.5 Sanofi S.A Key News
- 7.4 Dendreon Corporation
 - 7.4.1 Dendreon Corporation Corporate Summary
 - 7.4.2 Dendreon Corporation Business Overview
 - 7.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
 - 7.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
 - 7.4.5 Dendreon Corporation Key News
- 7.5 Bayer AG
 - 7.5.1 Bayer AG Corporate Summary
 - 7.5.2 Bayer AG Business Overview
 - 7.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Major Product Offerings
 - 7.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global Market (2017-2022)
 - 7.5.5 Bayer AG Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Opportunities & Trends in Global Market

Table 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers in Global Market

Table 3. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints in Global Market

Table 4. Key Players of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Global Market

Table 5. Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Type

Table 9. List of Global Tier 1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. Astellas Inc. Corporate Summary

Table 31. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings

Table 32. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Johnson & Johnson Corporate Summary

Table 34. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings

Table 35. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Sanofi S.A Corporate Summary

Table 37. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings

Table 38. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Dendreon Corporation Corporate Summary

Table 40. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings

Table 41. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Bayer AG Corporate Summary

Table 43. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offerings

Table 44. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Type in 2021

Figure 2. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Application in 2021

Figure 3. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Overview: 2020

Figure 4. Key Caveats

Figure 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in 2021

Figure 8. By Type - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Dendreon Corporation Castration-Resistant Prostate Cancer

(CRPC)/HRPCA Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/C1D190043670EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1D190043670EN.html>